Progressive Axonal Dysfunction Precedes Development of Neuropathy in Type 2 Diabetes

To evaluate the development of diabetic neuropathy, the current study examined changes in peripheral axonal function. Nerve excitability techniques were undertaken in 108 type 2 diabetic patients with nerve conduction studies (NCS), HbA(1c) levels, and total neuropathy score (TNS). Patients were cat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes (New York, N.Y.) N.Y.), 2012-06, Vol.61 (6), p.1592-1598
Hauptverfasser: SUNG, Jia-Ying, PARK, Susanna B, LIU, Ya-Ting, KWAI, Natalie, ARNOLD, Ria, KRISHNAN, Arun V, LIN, Cindy S.-Y
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1598
container_issue 6
container_start_page 1592
container_title Diabetes (New York, N.Y.)
container_volume 61
creator SUNG, Jia-Ying
PARK, Susanna B
LIU, Ya-Ting
KWAI, Natalie
ARNOLD, Ria
KRISHNAN, Arun V
LIN, Cindy S.-Y
description To evaluate the development of diabetic neuropathy, the current study examined changes in peripheral axonal function. Nerve excitability techniques were undertaken in 108 type 2 diabetic patients with nerve conduction studies (NCS), HbA(1c) levels, and total neuropathy score (TNS). Patients were categorized into two cohorts: patients with diabetes without neuropathy (DWN group [n = 56]) and patients with diabetes with neuropathy (DN group [n = 52]) and further into severity grade 0 (TNS 0-1 [n = 35]), grade 1 (TNS 2-8 [n = 42]), and grade 2/3 (TNS 9-24 [n = 31]). Results revealed that the DWN group had a significantly increased threshold, prolonged latency, and changes in excitability parameters compared with age-matched control subjects. Patients with neuropathy demonstrated significant alteration in recovery cycle parameters and depolarizing threshold electrotonus. Within the DWN cohort, there were significant correlations between HbA(1c) level and latency and subexcitability, whereas the estimated glomerular filtration rate correlated with superexcitability in patients with neuropathy. Furthermore, excitability parameters became progressively more abnormal with increasing clinical severity. These results suggest a spectrum of excitability abnormalities in patients with diabetes and that early axonal dysfunction may be detected prior to the development of neuropathy. As progressive changes in excitability parameters correlated to neuropathy severity, excitability testing may provide a biomarker of the early development and severity of diabetic neuropathy, providing insights into the pathophysiological mechanisms producing axonal dysfunction.
doi_str_mv 10.2337/db11-1509
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3357264</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A291497368</galeid><sourcerecordid>A291497368</sourcerecordid><originalsourceid>FETCH-LOGICAL-c527t-8e91469ae1c07c4ece74886cd7afd96a3fca831ec97d88a9539b35f0d9a691b63</originalsourceid><addsrcrecordid>eNpdkU1r3DAQhkVpaDZpD_0DRVAK7cGtPizJuhSWbNoEQpvDFnoTsjzeKHgtR7KX7r-PTLbbDwZmDvPwzseL0GtKPjLO1aemprSgguhnaEE11wVn6udztCCEsoIqrU7RWUr3hBCZ4wU6ZUwwJqlYoPVtDJsIKfkd4OWv0NsOr_apnXo3-tDj2wgOGkh4BTvowrCFfsShxd9gimGw490e-x6v9wNghlfe1jBCeolOWtsleHWo5-jHl8v1xVVx8_3r9cXypnCCqbGoQNNSagvUEeXKPEiVVSVdo2zbaGl562zFKTitmqqyWnBdc9GSRlupaS35Ofr8pDtM9RYal3eLtjND9Fsb9yZYb_7t9P7ObMLOcC4Uk2UWeH8QiOFhgjSarU8Ous72EKZkKKFCCVEJldG3_6H3YYr5XTPFGC-pzPlIbWwHxvdtyHPdLGqWLF-rFZdVpj48US6GlCK0x5UpMbOjZnbUzI5m9s3fNx7J3xZm4N0BsMnZro22dz794YQutRCMPwJc26f8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1022341622</pqid></control><display><type>article</type><title>Progressive Axonal Dysfunction Precedes Development of Neuropathy in Type 2 Diabetes</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Journals@Ovid Complete</source><creator>SUNG, Jia-Ying ; PARK, Susanna B ; LIU, Ya-Ting ; KWAI, Natalie ; ARNOLD, Ria ; KRISHNAN, Arun V ; LIN, Cindy S.-Y</creator><creatorcontrib>SUNG, Jia-Ying ; PARK, Susanna B ; LIU, Ya-Ting ; KWAI, Natalie ; ARNOLD, Ria ; KRISHNAN, Arun V ; LIN, Cindy S.-Y</creatorcontrib><description>To evaluate the development of diabetic neuropathy, the current study examined changes in peripheral axonal function. Nerve excitability techniques were undertaken in 108 type 2 diabetic patients with nerve conduction studies (NCS), HbA(1c) levels, and total neuropathy score (TNS). Patients were categorized into two cohorts: patients with diabetes without neuropathy (DWN group [n = 56]) and patients with diabetes with neuropathy (DN group [n = 52]) and further into severity grade 0 (TNS 0-1 [n = 35]), grade 1 (TNS 2-8 [n = 42]), and grade 2/3 (TNS 9-24 [n = 31]). Results revealed that the DWN group had a significantly increased threshold, prolonged latency, and changes in excitability parameters compared with age-matched control subjects. Patients with neuropathy demonstrated significant alteration in recovery cycle parameters and depolarizing threshold electrotonus. Within the DWN cohort, there were significant correlations between HbA(1c) level and latency and subexcitability, whereas the estimated glomerular filtration rate correlated with superexcitability in patients with neuropathy. Furthermore, excitability parameters became progressively more abnormal with increasing clinical severity. These results suggest a spectrum of excitability abnormalities in patients with diabetes and that early axonal dysfunction may be detected prior to the development of neuropathy. As progressive changes in excitability parameters correlated to neuropathy severity, excitability testing may provide a biomarker of the early development and severity of diabetic neuropathy, providing insights into the pathophysiological mechanisms producing axonal dysfunction.</description><identifier>ISSN: 0012-1797</identifier><identifier>EISSN: 1939-327X</identifier><identifier>DOI: 10.2337/db11-1509</identifier><identifier>PMID: 22522615</identifier><identifier>CODEN: DIAEAZ</identifier><language>eng</language><publisher>Alexandria, VA: American Diabetes Association</publisher><subject>Action Potentials - physiology ; Aged ; Axons ; Axons - physiology ; Biological and medical sciences ; Biomarkers ; Complications ; Complications and side effects ; Diabetes ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - physiopathology ; Diabetes. Impaired glucose tolerance ; Diabetic neuropathies ; Diabetic Neuropathies - physiopathology ; Diabetic neuropathy ; Disease Progression ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Female ; Hemoglobin ; Humans ; Male ; Medical sciences ; Middle Aged ; Morbidity ; Motor Neurons - physiology ; Muscle strength ; Muscle, Skeletal - physiopathology ; Neural Conduction - physiology ; Physiological aspects ; Polyneuropathies - physiopathology ; Research ethics ; Severity of Illness Index</subject><ispartof>Diabetes (New York, N.Y.), 2012-06, Vol.61 (6), p.1592-1598</ispartof><rights>2015 INIST-CNRS</rights><rights>COPYRIGHT 2012 American Diabetes Association</rights><rights>Copyright American Diabetes Association Jun 2012</rights><rights>2012 by the American Diabetes Association. 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c527t-8e91469ae1c07c4ece74886cd7afd96a3fca831ec97d88a9539b35f0d9a691b63</citedby><cites>FETCH-LOGICAL-c527t-8e91469ae1c07c4ece74886cd7afd96a3fca831ec97d88a9539b35f0d9a691b63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3357264/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3357264/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=25949552$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22522615$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SUNG, Jia-Ying</creatorcontrib><creatorcontrib>PARK, Susanna B</creatorcontrib><creatorcontrib>LIU, Ya-Ting</creatorcontrib><creatorcontrib>KWAI, Natalie</creatorcontrib><creatorcontrib>ARNOLD, Ria</creatorcontrib><creatorcontrib>KRISHNAN, Arun V</creatorcontrib><creatorcontrib>LIN, Cindy S.-Y</creatorcontrib><title>Progressive Axonal Dysfunction Precedes Development of Neuropathy in Type 2 Diabetes</title><title>Diabetes (New York, N.Y.)</title><addtitle>Diabetes</addtitle><description>To evaluate the development of diabetic neuropathy, the current study examined changes in peripheral axonal function. Nerve excitability techniques were undertaken in 108 type 2 diabetic patients with nerve conduction studies (NCS), HbA(1c) levels, and total neuropathy score (TNS). Patients were categorized into two cohorts: patients with diabetes without neuropathy (DWN group [n = 56]) and patients with diabetes with neuropathy (DN group [n = 52]) and further into severity grade 0 (TNS 0-1 [n = 35]), grade 1 (TNS 2-8 [n = 42]), and grade 2/3 (TNS 9-24 [n = 31]). Results revealed that the DWN group had a significantly increased threshold, prolonged latency, and changes in excitability parameters compared with age-matched control subjects. Patients with neuropathy demonstrated significant alteration in recovery cycle parameters and depolarizing threshold electrotonus. Within the DWN cohort, there were significant correlations between HbA(1c) level and latency and subexcitability, whereas the estimated glomerular filtration rate correlated with superexcitability in patients with neuropathy. Furthermore, excitability parameters became progressively more abnormal with increasing clinical severity. These results suggest a spectrum of excitability abnormalities in patients with diabetes and that early axonal dysfunction may be detected prior to the development of neuropathy. As progressive changes in excitability parameters correlated to neuropathy severity, excitability testing may provide a biomarker of the early development and severity of diabetic neuropathy, providing insights into the pathophysiological mechanisms producing axonal dysfunction.</description><subject>Action Potentials - physiology</subject><subject>Aged</subject><subject>Axons</subject><subject>Axons - physiology</subject><subject>Biological and medical sciences</subject><subject>Biomarkers</subject><subject>Complications</subject><subject>Complications and side effects</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetes Mellitus, Type 2 - physiopathology</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Diabetic neuropathies</subject><subject>Diabetic Neuropathies - physiopathology</subject><subject>Diabetic neuropathy</subject><subject>Disease Progression</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>Female</subject><subject>Hemoglobin</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Morbidity</subject><subject>Motor Neurons - physiology</subject><subject>Muscle strength</subject><subject>Muscle, Skeletal - physiopathology</subject><subject>Neural Conduction - physiology</subject><subject>Physiological aspects</subject><subject>Polyneuropathies - physiopathology</subject><subject>Research ethics</subject><subject>Severity of Illness Index</subject><issn>0012-1797</issn><issn>1939-327X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkU1r3DAQhkVpaDZpD_0DRVAK7cGtPizJuhSWbNoEQpvDFnoTsjzeKHgtR7KX7r-PTLbbDwZmDvPwzseL0GtKPjLO1aemprSgguhnaEE11wVn6udztCCEsoIqrU7RWUr3hBCZ4wU6ZUwwJqlYoPVtDJsIKfkd4OWv0NsOr_apnXo3-tDj2wgOGkh4BTvowrCFfsShxd9gimGw490e-x6v9wNghlfe1jBCeolOWtsleHWo5-jHl8v1xVVx8_3r9cXypnCCqbGoQNNSagvUEeXKPEiVVSVdo2zbaGl562zFKTitmqqyWnBdc9GSRlupaS35Ofr8pDtM9RYal3eLtjND9Fsb9yZYb_7t9P7ObMLOcC4Uk2UWeH8QiOFhgjSarU8Ous72EKZkKKFCCVEJldG3_6H3YYr5XTPFGC-pzPlIbWwHxvdtyHPdLGqWLF-rFZdVpj48US6GlCK0x5UpMbOjZnbUzI5m9s3fNx7J3xZm4N0BsMnZro22dz794YQutRCMPwJc26f8</recordid><startdate>20120601</startdate><enddate>20120601</enddate><creator>SUNG, Jia-Ying</creator><creator>PARK, Susanna B</creator><creator>LIU, Ya-Ting</creator><creator>KWAI, Natalie</creator><creator>ARNOLD, Ria</creator><creator>KRISHNAN, Arun V</creator><creator>LIN, Cindy S.-Y</creator><general>American Diabetes Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20120601</creationdate><title>Progressive Axonal Dysfunction Precedes Development of Neuropathy in Type 2 Diabetes</title><author>SUNG, Jia-Ying ; PARK, Susanna B ; LIU, Ya-Ting ; KWAI, Natalie ; ARNOLD, Ria ; KRISHNAN, Arun V ; LIN, Cindy S.-Y</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c527t-8e91469ae1c07c4ece74886cd7afd96a3fca831ec97d88a9539b35f0d9a691b63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Action Potentials - physiology</topic><topic>Aged</topic><topic>Axons</topic><topic>Axons - physiology</topic><topic>Biological and medical sciences</topic><topic>Biomarkers</topic><topic>Complications</topic><topic>Complications and side effects</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetes Mellitus, Type 2 - physiopathology</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Diabetic neuropathies</topic><topic>Diabetic Neuropathies - physiopathology</topic><topic>Diabetic neuropathy</topic><topic>Disease Progression</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>Female</topic><topic>Hemoglobin</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Morbidity</topic><topic>Motor Neurons - physiology</topic><topic>Muscle strength</topic><topic>Muscle, Skeletal - physiopathology</topic><topic>Neural Conduction - physiology</topic><topic>Physiological aspects</topic><topic>Polyneuropathies - physiopathology</topic><topic>Research ethics</topic><topic>Severity of Illness Index</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SUNG, Jia-Ying</creatorcontrib><creatorcontrib>PARK, Susanna B</creatorcontrib><creatorcontrib>LIU, Ya-Ting</creatorcontrib><creatorcontrib>KWAI, Natalie</creatorcontrib><creatorcontrib>ARNOLD, Ria</creatorcontrib><creatorcontrib>KRISHNAN, Arun V</creatorcontrib><creatorcontrib>LIN, Cindy S.-Y</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health &amp; Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health &amp; Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied &amp; Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Diabetes (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SUNG, Jia-Ying</au><au>PARK, Susanna B</au><au>LIU, Ya-Ting</au><au>KWAI, Natalie</au><au>ARNOLD, Ria</au><au>KRISHNAN, Arun V</au><au>LIN, Cindy S.-Y</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Progressive Axonal Dysfunction Precedes Development of Neuropathy in Type 2 Diabetes</atitle><jtitle>Diabetes (New York, N.Y.)</jtitle><addtitle>Diabetes</addtitle><date>2012-06-01</date><risdate>2012</risdate><volume>61</volume><issue>6</issue><spage>1592</spage><epage>1598</epage><pages>1592-1598</pages><issn>0012-1797</issn><eissn>1939-327X</eissn><coden>DIAEAZ</coden><abstract>To evaluate the development of diabetic neuropathy, the current study examined changes in peripheral axonal function. Nerve excitability techniques were undertaken in 108 type 2 diabetic patients with nerve conduction studies (NCS), HbA(1c) levels, and total neuropathy score (TNS). Patients were categorized into two cohorts: patients with diabetes without neuropathy (DWN group [n = 56]) and patients with diabetes with neuropathy (DN group [n = 52]) and further into severity grade 0 (TNS 0-1 [n = 35]), grade 1 (TNS 2-8 [n = 42]), and grade 2/3 (TNS 9-24 [n = 31]). Results revealed that the DWN group had a significantly increased threshold, prolonged latency, and changes in excitability parameters compared with age-matched control subjects. Patients with neuropathy demonstrated significant alteration in recovery cycle parameters and depolarizing threshold electrotonus. Within the DWN cohort, there were significant correlations between HbA(1c) level and latency and subexcitability, whereas the estimated glomerular filtration rate correlated with superexcitability in patients with neuropathy. Furthermore, excitability parameters became progressively more abnormal with increasing clinical severity. These results suggest a spectrum of excitability abnormalities in patients with diabetes and that early axonal dysfunction may be detected prior to the development of neuropathy. As progressive changes in excitability parameters correlated to neuropathy severity, excitability testing may provide a biomarker of the early development and severity of diabetic neuropathy, providing insights into the pathophysiological mechanisms producing axonal dysfunction.</abstract><cop>Alexandria, VA</cop><pub>American Diabetes Association</pub><pmid>22522615</pmid><doi>10.2337/db11-1509</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0012-1797
ispartof Diabetes (New York, N.Y.), 2012-06, Vol.61 (6), p.1592-1598
issn 0012-1797
1939-327X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3357264
source MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central; Journals@Ovid Complete
subjects Action Potentials - physiology
Aged
Axons
Axons - physiology
Biological and medical sciences
Biomarkers
Complications
Complications and side effects
Diabetes
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - physiopathology
Diabetes. Impaired glucose tolerance
Diabetic neuropathies
Diabetic Neuropathies - physiopathology
Diabetic neuropathy
Disease Progression
Endocrine pancreas. Apud cells (diseases)
Endocrinopathies
Etiopathogenesis. Screening. Investigations. Target tissue resistance
Female
Hemoglobin
Humans
Male
Medical sciences
Middle Aged
Morbidity
Motor Neurons - physiology
Muscle strength
Muscle, Skeletal - physiopathology
Neural Conduction - physiology
Physiological aspects
Polyneuropathies - physiopathology
Research ethics
Severity of Illness Index
title Progressive Axonal Dysfunction Precedes Development of Neuropathy in Type 2 Diabetes
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T20%3A39%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Progressive%20Axonal%20Dysfunction%20Precedes%20Development%20of%20Neuropathy%20in%20Type%202%20Diabetes&rft.jtitle=Diabetes%20(New%20York,%20N.Y.)&rft.au=SUNG,%20Jia-Ying&rft.date=2012-06-01&rft.volume=61&rft.issue=6&rft.spage=1592&rft.epage=1598&rft.pages=1592-1598&rft.issn=0012-1797&rft.eissn=1939-327X&rft.coden=DIAEAZ&rft_id=info:doi/10.2337/db11-1509&rft_dat=%3Cgale_pubme%3EA291497368%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1022341622&rft_id=info:pmid/22522615&rft_galeid=A291497368&rfr_iscdi=true